A study from PreciseDx showed that its artificial-intelligence-guided pathology test could help predict a patient’s chances of their breast cancer returning on par with a leading genomic approach. Working with real-world cancer data company COTA Healthcare, the former Fierce 15 winner put up its PreciseBreast test against Exact Sciences’ Oncotype DX, which delivers a personalized recurrence score […]
The post PreciseDx’s digital pathology AI on par with genomic testing in predicting breast cancer recurrence risks: study first appeared on Tissuepathology.com.↧